World Health Organization Issues Concern Over Severe Scarcity of Obesity Medications
Less than 10% of patients who could benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it issues its inaugural guidance on the therapies.
With more than one billion individuals worldwide now obese, it is urging more widespread and fairer availability to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The latest guidance affirms that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major obstacles to universal access to the jabs that can aid individuals in losing considerable body mass, says the agency.
Skinny Jab Shortage
Even in the present most favorable scenario, the production of these medications might only reach approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.
The advice encourages countries and companies to widen availability, via approaches such as voluntary licensing.
A patent on the active ingredient – the core component of the drug Wegovy – is set to lapse in multiple nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people consume fewer calories.
People usually see weight reduction within a few weeks of beginning the weekly injections.
Research indicates users may put most of the weight back on a year later of discontinuing the drug, when their normal hunger come back.
Being overweight or obese elevates your risk for developing medical conditions, like diabetes, heart disease, stroke, and some cancers.
Obesity concerns individuals in every country and was responsible for millions of deaths worldwide in 2024, as per the health agency.